title: Lactic acid bacteria: inhibition of angiotensin converting enzyme in vitro and in vivo.
abstract: A total of 26 strains of wild-type lactic acid bacteria, mainly belonging to Lactococcus lactis and Lactobacillus helveticus, were assayed in vitro for their ability to produce a milk fermentate with inhibitory activity towards angiotensin converting enzyme (ACE). It was clear that the test strains in this study, in general, produce inhibitory substances in varying amounts. Using a spectrophotometric assay based on amino group derivatization with ortho-phthaldialdehyde as a measure of relative peptide content, it was shown that there is a significant correlation between peptide formation and ACE inhibition, indicating that peptide measurement constitutes a convenient selection method. The effect of active fermentates on in vivo ACE activity was demonstrated in normotensive rats. The pressor effect of angiotensin I (0.3 microg/kg) upon intravenous injection was significantly lower when rats were pre-fed with milks fermented using two strains of Lactobacillus helveticus. An increased response to bradykinin (10 microg/kg, intravenously injected) was observed using one of these fermented milks. It is concluded that Lactobacillus helveticus produces substances which in vivo can give rise to an inhibition of ACE. The inhibition in vivo was low compared to what can be achieved with classical ACE inhibitors. The clinical relevance of this finding is discussed. This work is the first in which an effect of fermented milk on ACE in vivo has been demonstrated, measured as decreased ability to convert angiotensin I to angiotensin II.
authors.affiliation: Royal Danish School of Pharmacy, 2 Universitetsparken. DK-2100 Copenhagen O, Denmark. anfu@mail.dfh.dk
authors.forename: Anders
authors.initials: A
authors.lastname: Fuglsang
authors.forename: Fergal P
authors.initials: FP
authors.lastname: Rattray
authors.forename: Dan
authors.initials: D
authors.lastname: Nilsson
authors.forename: Niels C B
authors.initials: NC
authors.lastname: Nyborg
mesh_terms: D000803:Angiotensin I / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000378:metabolism; D005285:Fermentation; D007778:Lactobacillus / Q000378:metabolism*; D013294:Lactococcus lactis / Q000378:metabolism*; D008297:Male; D008892:Milk / Q000378:metabolism / Q000382:microbiology*; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D009764:o-Phthalaldehyde / Q000378:metabolism
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D009764:o-Phthalaldehyde; D000803:Angiotensin I; D007703:Peptidyl-Dipeptidase A; D001920:Bradykinin